Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CVKD | Common Stock | Conversion of derivative security | +515K | +1286.98% | 555K | Jan 24, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CVKD | Convertible Promissory Note | Conversion of derivative security | -515K | -100% | 0 | Jan 24, 2023 | Common Stock | 515K | $1.00 | Direct | F1 |
Id | Content |
---|---|
F1 | Upon consummation of the initial public offering of Cadrenal Therapeutics, Inc. on January 24, 2023, Mr. Murphy was issued 514,792 shares of common stock pursuant to the conversion of a convertible promissory note in the principal amount of $500,000, based on a conversion price of $1.00 per share. |